Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread.
Eur J Med Chem. 2021 Nov 5;223:113601. doi: 10.1016/j.ejmech.2021.113601. Epub 2021 Jun 5.
Eur J Med Chem. 2021.
PMID: 34153575